S&P 500   3,381.30 (+1.37%)
DOW   27,932.65 (+1.75%)
QQQ   280.38 (+1.61%)
AAPL   116.62 (+2.22%)
MSFT   211.80 (+2.19%)
FB   264.14 (+0.90%)
GOOGL   1,479.15 (+0.90%)
AMZN   3,203.51 (+1.86%)
TSLA   429.13 (+2.40%)
NVDA   543.48 (+2.73%)
BABA   292.06 (+5.46%)
CGC   14.56 (+0.41%)
GE   6.26 (+2.29%)
MU   48.06 (-5.23%)
AMD   82.15 (+0.46%)
T   28.53 (+0.81%)
F   6.68 (+1.21%)
ACB   4.75 (+1.50%)
GILD   62.91 (+1.30%)
NFLX   500.74 (+1.47%)
DIS   124.76 (-0.51%)
BA   167.75 (+2.54%)
BAC   24.18 (+1.72%)
S&P 500   3,381.30 (+1.37%)
DOW   27,932.65 (+1.75%)
QQQ   280.38 (+1.61%)
AAPL   116.62 (+2.22%)
MSFT   211.80 (+2.19%)
FB   264.14 (+0.90%)
GOOGL   1,479.15 (+0.90%)
AMZN   3,203.51 (+1.86%)
TSLA   429.13 (+2.40%)
NVDA   543.48 (+2.73%)
BABA   292.06 (+5.46%)
CGC   14.56 (+0.41%)
GE   6.26 (+2.29%)
MU   48.06 (-5.23%)
AMD   82.15 (+0.46%)
T   28.53 (+0.81%)
F   6.68 (+1.21%)
ACB   4.75 (+1.50%)
GILD   62.91 (+1.30%)
NFLX   500.74 (+1.47%)
DIS   124.76 (-0.51%)
BA   167.75 (+2.54%)
BAC   24.18 (+1.72%)
S&P 500   3,381.30 (+1.37%)
DOW   27,932.65 (+1.75%)
QQQ   280.38 (+1.61%)
AAPL   116.62 (+2.22%)
MSFT   211.80 (+2.19%)
FB   264.14 (+0.90%)
GOOGL   1,479.15 (+0.90%)
AMZN   3,203.51 (+1.86%)
TSLA   429.13 (+2.40%)
NVDA   543.48 (+2.73%)
BABA   292.06 (+5.46%)
CGC   14.56 (+0.41%)
GE   6.26 (+2.29%)
MU   48.06 (-5.23%)
AMD   82.15 (+0.46%)
T   28.53 (+0.81%)
F   6.68 (+1.21%)
ACB   4.75 (+1.50%)
GILD   62.91 (+1.30%)
NFLX   500.74 (+1.47%)
DIS   124.76 (-0.51%)
BA   167.75 (+2.54%)
BAC   24.18 (+1.72%)
S&P 500   3,381.30 (+1.37%)
DOW   27,932.65 (+1.75%)
QQQ   280.38 (+1.61%)
AAPL   116.62 (+2.22%)
MSFT   211.80 (+2.19%)
FB   264.14 (+0.90%)
GOOGL   1,479.15 (+0.90%)
AMZN   3,203.51 (+1.86%)
TSLA   429.13 (+2.40%)
NVDA   543.48 (+2.73%)
BABA   292.06 (+5.46%)
CGC   14.56 (+0.41%)
GE   6.26 (+2.29%)
MU   48.06 (-5.23%)
AMD   82.15 (+0.46%)
T   28.53 (+0.81%)
F   6.68 (+1.21%)
ACB   4.75 (+1.50%)
GILD   62.91 (+1.30%)
NFLX   500.74 (+1.47%)
DIS   124.76 (-0.51%)
BA   167.75 (+2.54%)
BAC   24.18 (+1.72%)
Log in
NASDAQ:ERYP

Erytech Pharma Stock Forecast, Price & News

$5.98
+0.18 (+3.10 %)
(As of 09/30/2020 03:45 AM ET)
Add
Compare
Today's Range
$5.98
Now: $5.98
$5.98
50-Day Range
$5.70
MA: $6.80
$7.74
52-Week Range
$3.50
Now: $5.98
$13.95
Volume154 shs
Average Volume4,134 shs
Market Capitalization$108.13 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Read More
Erytech Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.55 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ERYP
CUSIPN/A
CIKN/A
Phone33-4-78-74-44-38

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.34 per share

Profitability

Miscellaneous

Employees172
Market Cap$108.13 million
Next Earnings DateN/A
OptionableNot Optionable
$5.98
+0.18 (+3.10 %)
(As of 09/30/2020 03:45 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions

How has Erytech Pharma's stock price been impacted by Coronavirus?

Erytech Pharma's stock was trading at $5.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ERYP shares have increased by 14.1% and is now trading at $5.98.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Erytech Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Erytech Pharma
.

Are investors shorting Erytech Pharma?

Erytech Pharma saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 500 shares, an increase of 25.0% from the August 31st total of 400 shares. Based on an average daily volume of 3,700 shares, the short-interest ratio is currently 0.1 days.
View Erytech Pharma's Short Interest
.

Who are some of Erytech Pharma's key competitors?

What other stocks do shareholders of Erytech Pharma own?

Who are Erytech Pharma's key executives?

Erytech Pharma's management team includes the following people:
  • Mr. Gil Beyen, Chairman & CEO (Age 57)
  • Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
  • Mr. Eric Soyer, CFO & COO (Age 53)
  • Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
  • Naomi Eichenbaum, Director Investor Relations

When did Erytech Pharma IPO?

(ERYP) raised $125 million in an initial public offering on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.

What is Erytech Pharma's stock symbol?

Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."

How do I buy shares of Erytech Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Erytech Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $5.98.

How big of a company is Erytech Pharma?

Erytech Pharma has a market capitalization of $108.13 million. The company earns $-70,180,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Erytech Pharma employs 172 workers across the globe.

What is Erytech Pharma's official website?

The official website for Erytech Pharma is www.erytech.com.

How can I contact Erytech Pharma?

Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.